'Iron Lung' and the Future of Filmmaking
These Athletes Are Getting Paid to Shame Their Own Country at the Olympics
WaPo CEO Resigns Days After Laying Off 300 Employees
Georgia's Jon Ossoff Says Trump Administration Imitates Rhetoric of 'History's Worst Regim...
U.S. Thwarts $4 Million Weapons Plot Aimed at Toppling South Sudan Government
Minnesota Mom, Daughter, and Relative Allegedly Stole $325k from SNAP
Michigan AG: Detroit Man Stole 12 Identities to Collect Over $400,000 in Public...
Does Maxine Waters Really Think Trump Will Be Bothered by Her Latest Tantrum?
Fifth Circuit Rules That Some Illegal Aliens Can Be Detained Without Bond Until...
Just Days After Mass Layoffs, WaPo Returns to Lying About the Trump Admin
Nigerian Man Sentenced to Over 8 Years for International Inheritance Fraud Targeting Elder...
Florida's Crackdown on Non-English Speaking Drivers Is Hilarious
Family Fraud: Father, Two Daughters Convicted in $500k USDA Nutrition Program Scam
American Olympians Bash Their Own Country As Democrats and Media Gush
Speculation Into Iran Strike Continues As Warplanes Are Pulled From Super Bowl Flyover...
Tipsheet

Moderna Plans to Roll Out Booster Dose to Combat Delta Variant

AP Photo/Rogelio V. Solis

On Thursday, Moderna President Dr. Stephen Hoge reportedly told investors and analysts that it’s planning for a booster dose for its two-dose mRNA COVID-19 vaccine to combat the contagious delta variant in the coming months. The company also reported in a lengthy press release issued Thursday that the two-dose vaccine maintains 93 percent efficacy six months after the second dose.

Advertisement

In the press release, Moderna shared several announcements regarding the findings of studies on the current two-dose COVID-19 vaccine as well as insight regarding a booster vaccine in the future.

“We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” CEO Stéphane Bancel said in a statement published on Thursday. “We have begun preparing late stage studies for our flu vaccine and RSV vaccine, which received fast track designation from the FDA a few days ago and are looking forward towards our vision of a single dose annual booster that provides protection against COVID-19, flu and RSV for adults.”

An image circulating on Twitter, reportedly from Moderna, shows a breakdown of the company’s perspective on the trajectory of the pandemic in coming months. The “booster strategy” is the proposed solution to combat the intersection between the delta variant and seasonal changes, among other things, that may result in breakthrough cases of COVID-19 in vaccinated individuals.

Advertisement

“We believe that increased force of infection resulting from Delta, non-pharmaceutical intervention (NPI) fatigue, and seasonal effects (moving indoors) will lead to an increase of breakthrough infections in vaccinated individuals,” the image states. “[W]e believe dose 3 booster will likely be necessary prior to the winter season.”

This news of a booster dose comes right after the World Health Organization’s Director-General Tedros Adhanom Ghebreyesus called for halting vaccine boosters until the end of September in favor of individuals in lower income countries who’ve not yet had access to the vaccine. However, Germany, France and Israel have already administered or plan to administer booster doses to qualifying individuals in the near future. As of right now, the United States does not have booster doses available for vaccinated individuals.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement